Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Core Insights - Ibalizumab shows long-term efficacy and safety in reducing HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug-resistant HIV [1][2][6] - The PROMISE-US study indicates that patients on ibalizumab-containing regimens achieve similar rates of undetectable viral loads compared to those on non-ibalizumab regimens, despite having more severe HIV disease at baseline [2][4] Study Details - The PROMISE-US study is a phase 4, multicenter, observational registry study designed to assess the efficacy and durability of ibalizumab in combination with other antiretroviral therapies [3][6] - The interim analysis included 112 participants, with 70 in the non-ibalizumab cohort and 42 in the ibalizumab cohort, showing baseline viremia rates of 39% and 57% respectively [4] Treatment Outcomes - Among participants with baseline viremia, 50% of those in the non-ibalizumab cohort and 47% in the ibalizumab cohort achieved undetectable viral loads after six months [5] - At 12 months, 53% of the non-ibalizumab cohort and 42% of the ibalizumab cohort had undetectable viral loads [5] Safety Profile - Ibalizumab was well-tolerated, with no infusion reactions reported and no treatment discontinuations due to adverse events in the ibalizumab cohort [5]